Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
127.85
+0.10 (0.08%)
Aug 15, 2025, 4:00 PM - Market closed
Insmed Stock Forecast
Stock Price Forecast
The 15 analysts that cover Insmed stock have a consensus rating of "Strong Buy" and an average price target of $137.4, which forecasts a 7.47% increase in the stock price over the next year. The lowest target is $101 and the highest is $240.
Price Target: $137.4 (+7.47%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Insmed stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 8 | 8 | 9 | 9 | 9 | 9 |
Buy | 8 | 8 | 8 | 8 | 8 | 8 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 16 | 16 | 17 | 17 | 17 | 17 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Truist Securities | Truist Securities | Strong Buy Maintains $126 → $139 | Strong Buy | Maintains | $126 → $139 | +8.72% | Aug 14, 2025 |
Stifel | Stifel | Strong Buy Maintains $121 → $145 | Strong Buy | Maintains | $121 → $145 | +13.41% | Aug 14, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $120 → $240 | Strong Buy | Maintains | $120 → $240 | +87.72% | Aug 13, 2025 |
UBS | UBS | Strong Buy Maintains $133 → $140 | Strong Buy | Maintains | $133 → $140 | +9.50% | Aug 13, 2025 |
RBC Capital | RBC Capital | Buy Maintains $120 → $138 | Buy | Maintains | $120 → $138 | +7.94% | Aug 13, 2025 |
Financial Forecast
Revenue This Year
466.39M
from 363.71M
Increased by 28.23%
Revenue Next Year
1.03B
from 466.39M
Increased by 119.99%
EPS This Year
-5.40
from -5.57
EPS Next Year
-3.78
from -5.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 500.4M | 1.5B | 2.4B | ||
Avg | 466.4M | 1.0B | 1.9B | ||
Low | 356.7M | 829.1M | 1.4B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 37.6% | 217.5% | 138.5% | ||
Avg | 28.2% | 120.0% | 87.4% | ||
Low | -1.9% | 77.8% | 39.4% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -5.17 | -2.45 | 1.45 | ||
Avg | -5.40 | -3.78 | -0.85 | ||
Low | -5.89 | -5.46 | -2.68 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.